AP NEWS

KCR Expands its Service Portfolio with Trial Execution Consulting

July 5, 2018

BOSTON--(BUSINESS WIRE)--Jul 5, 2018--KCR, a full-service contract research organization, is extending its service portfolio with Trial Execution Consulting to support clients in translating scientific objectives into operational activity. The new service is primarily dedicated to biotechnology companies as well as small and medium pharma.

“Our new service is structured and focused on enabling operational delivery for our clients,” said Dr. Anna Baran, chief medical officer at KCR and head of the Trial Execution Consulting service. “The clinical research industry has become very complex nowadays, with great time and cost pressure. Having executed multiple projects of high complexity and following years of active collaboration with national and local authorities, we are well equipped to share our wealth of knowledge and expertise.”

Trial Execution Consulting covers all areas required for successful execution of the trial including medical expertise, regulatory affairs and operational guidance. The service focuses on transparency in delivering a variety of solutions with quantifying clearly risks and benefits.

“Consulting has already been an integral part of our projects, especially high-risk studies requiring complex market expertise. Our clients appreciate our direct approach and broad perspective in providing possible scenarios for their study execution,” said Dr. Baran. “We fully understand the timelines as well as operational needs to deliver projects effectively.”

Bolstered by more than 20 years of experience in the clinical trial market, KCR offers customized solutions and designs effective execution strategies for clients. With four hubs located in Boston, U.S.; Berlin, Germany; Warsaw, Poland; and Kiev, Ukraine, KCR is uniquely positioned to conduct significantly challenging clinical research studies.

“Our company strives for continuous development, so we are taking the next step in KCR’s evolution,” summarized Mike Jagielski, president and chief executive officer of KCR. “The new service is a great opportunity to assist our biotech and pharma clients in being successful with their studies on an international level. By adding Trial Execution Consulting to our services portfolio, we can continue to offer boutique, customized and fully responsive solutions to meet our clients’ specific requests.”

If you would like to learn more about KCR services and its new Trial Execution Consulting service, please email Joanna Lewandowska, public relations and marketing, at Joanna.lewandowska@kcrcro.com.

About KCR

KCR is a contract research organization providing clinical development solutions for the pharmaceutical, biotechnology and medical device industries. The company supports clients with full-service capabilities across three main services: Trial Execution (TE), Functional Service Provision (FS) and Trial Execution Consulting (TC) over a broad range of therapeutic areas. KCR operates across four main regions: North America, Western Europe, Central Europe, and Eastern Europe with hubs located in Boston, U.S., Berlin, Germany, Warsaw, Poland and Kiev, Ukraine. KCR’s geographical locations allow for optimized delivery of trial execution strategies to develop life-changing therapies. For more information, visit  www.kcrcro.com.

KCR: We see human behind every number.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180705005085/en/

CONTACT: KCR

Joanna Lewandowska

Associate Director, PR & Marketing

Mob: +48 605 053 164

Email:joanna.lewandowska@kcrcro.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL PROFESSIONAL SERVICES CONSULTING GENERAL HEALTH

SOURCE: KCR

Copyright Business Wire 2018.

PUB: 07/05/2018 06:00 AM/DISC: 07/05/2018 06:01 AM

http://www.businesswire.com/news/home/20180705005085/en

AP RADIO
Update hourly